Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2018; 9(17):3149-3155. doi:10.7150/jca.25395 This issue Cite

Research Paper

Covalent CDK7 Inhibitor THZ1 Inhibits Myogenic Differentiation

Xinqi Ma1, Xielan Kuang1,2, Qing Xia1, Zixin Huang1, Yuting Fan1, Jie Ning1, Jiajie Wen1, Han Zhang1, Jianhua Yan1, Qingjiong Zhang1, Huangxuan Shen1,2✉, Chongde Long1✉

1. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, 54 Xianlie Road, Guangzhou 510060, China.
2. Biobank of Eye, State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, 54 Xianlie Road, Guangzhou 510060, China

✉ Corresponding authors: Huangxuan Shen, Ph.D., Zhongshan Ophthalmic Center, Sun Yat-sen University, 54 Xianlie Road, Guangzhou 510060, China. Phone: (+8620)-8733-5261; FAX: (+8620)-8733-3271; Email: shenhxsysu.edu.cn. Chongde Long, Ph.D., M.D., More

Citation:
Ma X, Kuang X, Xia Q, Huang Z, Fan Y, Ning J, Wen J, Zhang H, Yan J, Zhang Q, Shen H, Long C. Covalent CDK7 Inhibitor THZ1 Inhibits Myogenic Differentiation. J Cancer 2018; 9(17):3149-3155. doi:10.7150/jca.25395. https://www.jcancer.org/v09p3149.htm
Other styles

File import instruction

Abstract

Covalent CDK7 inhibitor THZ1 is a newly discovered anti-tumor drug.THZ1 affects the function of transcription factor TFIIH by inhibiting CDK7, which in turn affects RNA polymerase II, and ultimately affects transcription initiation. Study found that THZ1 could inhibit proliferation and promote apoptosis of several tumor cell lines. However, there is no report of the potential side effect of THZ1 in normal tissues. In the course of cancer, the muscle consumption of cachexia needs to be supplemented by the differentiation of muscle cells. However, the effect of THZ1 on myogenic differentiation remains unclear. Our study in this article found that THZ1 could both inhibit the differentiation of C2C12 cells and mouse primary myoblasts, also repressing the expression of differentiation-related transcription factors and muscle structural proteins, such as and myogenin, myh3 and MCK. Moreover, THZ1 could inhibit C2C12 cell proliferation and migration, increase its oxidative stress and promote its apoptosis. Our data indicates that THZ1 inhibits myogenic differentiation, suggesting that therapies based on THZ1 might have potential side effects on muscle functions.

Keywords: THZ1, Cachexia, C2C12 cells, myogenic differentiation

Citation styles

APA
Ma, X., Kuang, X., Xia, Q., Huang, Z., Fan, Y., Ning, J., Wen, J., Zhang, H., Yan, J., Zhang, Q., Shen, H., Long, C. (2018). Covalent CDK7 Inhibitor THZ1 Inhibits Myogenic Differentiation. Journal of Cancer, 9(17), 3149-3155. https://doi.org/10.7150/jca.25395.

ACS
Ma, X.; Kuang, X.; Xia, Q.; Huang, Z.; Fan, Y.; Ning, J.; Wen, J.; Zhang, H.; Yan, J.; Zhang, Q.; Shen, H.; Long, C. Covalent CDK7 Inhibitor THZ1 Inhibits Myogenic Differentiation. J. Cancer 2018, 9 (17), 3149-3155. DOI: 10.7150/jca.25395.

NLM
Ma X, Kuang X, Xia Q, Huang Z, Fan Y, Ning J, Wen J, Zhang H, Yan J, Zhang Q, Shen H, Long C. Covalent CDK7 Inhibitor THZ1 Inhibits Myogenic Differentiation. J Cancer 2018; 9(17):3149-3155. doi:10.7150/jca.25395. https://www.jcancer.org/v09p3149.htm

CSE
Ma X, Kuang X, Xia Q, Huang Z, Fan Y, Ning J, Wen J, Zhang H, Yan J, Zhang Q, Shen H, Long C. 2018. Covalent CDK7 Inhibitor THZ1 Inhibits Myogenic Differentiation. J Cancer. 9(17):3149-3155.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use